LONDON, April 21, 2015 /PRNewswire/ --
Whitehall-based consultancy celebrates Queen's Award for Enterprise, having achieved dazzling export-led growth in just 4 years.
PharmaGenesis London™ today celebrates its part in winning the Queen's Award for Enterprise, for Outstanding Achievement in International Trade, awarded to Oxford PharmaGenesis. As part of the world's first HealthScience Communications consultancy, PharmaGenesis London helps its clients bring new medicines to the world in areas of patient need. PharmaGenesis London™ has more than quadrupled its exports in just 3 years, from £280,000 in 2012 to £1.3 million in 2014. Approximately 90% of its income is earned abroad.
PharmaGenesis London™ has grown steadily through repeat business and personal recommendation since Dr Catherine Hill opened the office in 2012. From premises overlooking Trafalgar Square, the company's 14 London-based employees now work with pharmaceutical clients around the world: 67% of its business is from mainland Europe and 22% from the USA. To support its global client base, PharmaGenesis London™ works closely with colleagues in Basel and Philadelphia, as well as in Oxford.
The success of PharmaGenesis London™ upholds the enduring power of the London name. Around the world, London has a reputation for high standards of science and medicine, and excellence in publishing. Dr Chris Winchester, Managing Director, comments, "London also means something more - energy and hard work, enabling us to get it right for the patients, clinicians and clients we work with every day."
PharmaGenesis London™ anticipates creating further highly skilled jobs. London offers an unrivalled pool of talented scientists and doctors with a flair for clear communication. It works hard to retain the talented people it recruits and develops, and clients value the continuity this approach provides. "Ours is a hugely satisfying company to work for, whose success is only made possible through the efforts of our high-performing teams," says Dr Richard White, Commercial Director.
As Oxford PharmaGenesis continues to grow its business around the world, London will remain a key part of the company's success. Dr Chris Winchester, Managing Director, said, "As a proudly independent company owned by UK-based employee shareholders, we have the freedom to make the right decisions for our company, our clients and our employees. At Oxford PharmaGenesis, we are delighted to receive this prestigious award. We are looking forward to joining other award winners at Buckingham Palace later in the year."
Notes for Editors
About the Queen's Award
- Now in its 50th anniversary year, the Queen's Award for Enterprise is the UK's highest accolade for business success, and provides an opportunity to celebrate and encourage excellence in UK business.
- Awards are made in three categories, International Trade, Innovation, and Sustainable Development, and are valid for 5 years.
- Applications are made in September each year, audited by qualified accountants and considered by an Advisory Committee that includes representatives of Government, industry and commerce, and trade unions.
- Awards are made by the Queen on the advice of the Prime Minister, and publicly announced on the Queen's birthday, 21 April.
- Winners are invited to attend a reception at Buckingham Palace in July.
- The Lord-Lieutenant of the County (the Queen's representative in Oxfordshire) will present a Grant of Appointment and crystal bowl at our Oxford headquarters later in the year.
- Approximately 160 awards are made a year, with roughly 20% of applicants being successful.
- Previous winners of a Queen's Award for International Trade include Jaguar Land Rover (2014), Hackett (2012), and the FA Premier League (2010).
About PharmaGenesis London™
- PharmaGenesis London™, the London office of Oxford PharmaGenesis Ltd, opened in 2012 and has 14 dedicated HealthScience experts, 8 of whom are educated to PhD level or above.
- The office's top 5 overseas markets are Switzerland (63% of total sales), USA (22%), and the rest of the EU (5%). UK clients account for only 10% of sales.
- Overseas sales more than quadrupled in four years from £280,000 in financial year ending 31 October 2010 to £1.3 million in year ending 31 October 2013 (up 377%). Over the same period, total sales increased more than five times, from £280,000 to £1.5 million (up 436%), and employees from 1 to 14 (up 1400%).
About Oxford PharmaGenesis
- Oxford PharmaGenesis Ltd is an independent, privately owned consultancy established in 1998 and has 110 dedicated HealthScience experts working in offices in Oxford and London, 42 of whom are educated to PhD level or above.
- The company's top 5 overseas markets are Switzerland (44% of total sales), USA (21%), Sweden (12%), Germany (7%) and France (2%). UK clients account for only 11% of sales.
- Overseas sales more than doubled in four years from £4.0 million in financial year ending 31 October 2010 to £8.9 million in year ending 31 October 2013 (up 123%). Over the same period, total sales nearly doubled from £5.1 million to £10.0 million (up 95%), and employees from 63 to 108 (up 44%).
- The company has further offices in Basel and Philadelphia which employ a further 17 people and generate in excess of an additional £2 million in sales.
- Oxford PharmaGenesis has eight specialist practices, in medical communications, publications, value demonstration, real-world evidence, regulatory, orphan drugs, policy and commercialization.
- It takes a leadership position by exhibiting and presenting at international meetings such as the International Society of Medical Publication Professionals, the International Publication Planning Association, the International Society for Pharmacoeconomics and Outcomes Research, the International Society of Pharmacoepidemiology and the World Orphan Drug Congress.
The Queen's Award for Enterprise Magazine, 2015. Available from http://www.queensawardsmagazine.com/awardwinners/search, accessed 9 April 2015
Corfield R. The small, sane voices of big pharma. Oxford Times InBusiness Magazine, 15 May 2014, page 27 Available from http://www.oxfordtimes.co.uk/business/profiles/11210021.The_small__sane_voices_of_big_pharma/; accessed 9 April 2015.
Oxford PharmaGenesis website. http://www.pharmagenesis.com/ ; accessed 9 April 2015.
For further information, please contact:
Dr Catherine Hill
Communications Director, PharmaGenesis London™
Dr Chris Winchester
Managing Director, Oxford PharmaGenesis
SOURCE PharmaGenesis London